Clinical Trial Detail

NCT ID NCT01316757
Title Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

salivary gland cancer

larynx verrucous carcinoma

oral cavity cancer

head and neck squamous cell carcinoma

Therapies

Carboplatin + Cetuximab + Erlotinib + Paclitaxel

Age Groups: adult

No variant requirements are available.